- Home
- Equipment
- usa maryland
- gene therapies
Refine by
Applications
- Medical Device Solutions for Full Lifecycle
- Medical Device Solutions for Opportunity Realization
- Duodenal Mucosal Resurfacing System (DMR) for Type 2 Diabetes
- Duodenal Mucosal Resurfacing System (DMR) for Clinical Research Studies
- Duodenal Mucosal Resurfacing System (DMR) for T2Di Study
- Duodenal Mucosal Resurfacing System (DMR) for Healthcare Professionals
- Liposomes - Hollow Nanospheres for Gene Therapy
- Liposomes - Hollow Nanospheres for Cancer Therapy
- Liposomes - Hollow Nanospheres for Ocular Drug Delivery
- Liposomes - Hollow Nanospheres for Brain Drug Delivery
- Liposomes - Hollow Nanospheres for Vaccines
- Liposomes - Hollow Nanospheres for Immunomodulating Response
- Liposomes - Hollow Nanospheres for Tissue Engineering
Gene Therapies Equipment & Supplies Near Usa Maryland
120 equipment items found
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
BRAF encodes a serine/threonine protein kinase, which plays an important role in signaling pathways involved in cell proliferation and differentiation. Determination of BRAF V600 mutational status is recommended in metastatic colorectal cancer (mCRC) at the same time as RAS mutational status for prognostic assessment (and/or potential selection for clinical trials). Testing of patients with ...
Manufactured by:ViruSure GmbH based inVienna, AUSTRIA
Gene therapy has brought hope to many diseases with unmet clinical need. The potential to permanently cure the patient through replacement of a defective gene with a healthy gene underscores the surge of interest in this exciting biopharma ...
Manufactured by:Novartis International AG based inBasel, SWITZERLAND
Our investigational gene therapy, GT005, is designed to restore balance to a part of our immune system called the complement ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to ...
Manufactured by:Obsidian Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® ...
Manufactured by:Clearside Biomedical based inAlpharetta, GEORGIA (US) (USA)
We believe our platform offers the potential for safer, targeted ocular gene therapy without some of the risks of surgery and subretinal administration. Suprachoroidal administration of gene therapy could ultimately enhance access to care because it does not require specialized gene therapy ...
Manufactured by:Albian Group based inBilbao, SPAIN
A physical barrier between a process that may require sterility and pressurisation, either positive or negative, from the outside environment, ensuring the necessary protection, reducing potential contamination and risks of cross-contamination and achieving the required air quality in the respective areas. ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. ...
Manufactured by:Zhejiang Tailin Bioengineering Co., Ltd. based inBinjiang, Hangzhou, CHINA
Design based on stringent GMP aseptic production requirements and meets the requirements of various regulatory agencies (FDA, EMA, NMPA) regulations and industry guidelines (ISO, PDA, USP, Chinese ...
Manufactured by:Unchained Labs based inPleasanton, CALIFORNIA (USA)
Stunner is the only system that pulls together UV/Vis concentration, Dynamic Light Scattering (DLS) and Static Light Scattering (SLS) data from the same 2 μL sample. Dig in to your AAV to get the total capsid titer and empty/full ratio, or rack up payload concentration and size data on any nanoparticle all at once. Nail down your protein quality by knocking concentration, hydrodynamic size, ...
Manufactured by:Holostem Terapie Avanzate S.r.l. based inModena, ITALY
Epidermolysis Bullosa (EB) is a group of genetic adhesion disorders characterized by fragility of the skin. EB are devastating, highly disfiguring, blistering pathologies that severely impairs the quality of life of patients and affect approximately 500,000 people worldwide ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases (“IRDs”). It consists of a functional copy of a nuclear hormone receptor (“NHR”) gene, NR2E3, delivered to ...
Manufactured by:IGEA S.P.A. based inCarpi, ITALY
Incorporates a commercial syringe housing, guiding the injection to the centre of the electroporation volume. Easy control of needle insertion depth, as needles remain in the guide. Option to inject to different depths. Mechanical retraction of the syringe with a special trigger before ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
Ocugen’s modifier gene therapy platform is a cutting-edge technology licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School) and involves targeted delivery and expression of one or more nuclear hormone receptor genes (NHRs) in the disease tissues. ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta’s wholly owned gene therapy program for the treatment of ornithine transcarbamylase (OTC) deficiency is expected to enter the clinic in 2022. OTC deficiency is a genetic disorder urea cycle that causes ammonia to accumulate in the blood. The most severe form of the disorder presents within the first few days of life. ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta’s first ImmTORTM + gene therapy candidate MMA-101 for methylmalonic acidemia (MMA) is expected to enter clinical trials the end of 2021. MMA is a rare metabolic disease that may lead to metabolic acidosis and hyperammonemia and is associated with long-term complications including feeding problems, developmental delay, intellectual disability, and ...
Manufactured by:XyloCor Therapeutics based inWayne, PENNSYLVANIA (USA)
XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Genetic diseases are caused by defective genes. Gene replacement therapy aims to treat such diseases by introducing a corrective gene into a patient’s body; the corrective gene can be a normal copy of the defective gene, or a copy that is engineered to provide enhanced biological activity; ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Genome editing technologies enables permanent modifications to the genome by harnessing the activities of certain enzymes (e.g. nucleases and integrase) and invoking DNA repair mechanisms at specific locations in the genome. As a therapeutic modality, genome editing can correct a defective gene, disrupt a deleterious gene, or target a therapeutic gene to a precise location in the genome for safe ...